The Phase 2 dose-finding trial (N=338), published in the New England Journal of Medicine in 2023 (DOI: 10.1056/NEJMoa2301972), randomized participants with obesity (BMI 30-50) to retatrutide at doses ranging from 0.5mg to 12mg weekly or placebo over 48 weeks
What matters most is not the number itself but the supervised process that determines whether any higher level is appropriate, including a providers ongoing review of tolerance, health history, and treatment goals
This can lead to headaches, fatigue, dizziness, and muscle cramps that get misattributed to the medication itself
Relative changes in resting energy expenditure during weight loss: a systematic review
Another lost 17.5%
For more information: Macrene Alexiades, MD, PhD, FAAD, is director and founder of the Dermatology & Laser Center of New York and a Healio Dermatology Peer Perspective Board Member